Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
Status:
Completed
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for
subjects with different homologous recombination deficiency (HRD) tumor status and with
platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer.
Subjects should have received at least 1 prior line of platinum-based chemotherapy.